Australia’s active vaccine safety system
New AusVaxSafety research has provided reassuring evidence that receiving an mpox vaccine at the same appointment as other vaccines was not associated with increased rates of adverse events.
The study, published in Eurosurveillance, analysed AusVaxSafety (Australia’s active vaccine safety surveillance system) data from 10,943 adults who received the modified vaccinia Ankara-Bavarian Nordic (MVA-BN) mpox vaccine during Australia’s 2022–23 mpox vaccination program.
Researchers found that people who received another vaccine at the same time as their mpox vaccine reported similar rates of adverse events, medical attendance and impacts on routine activities compared with those who received the mpox vaccine alone.
While only 1.8% of participants received another vaccine during the same visit, co-administration was most commonly reported with COVID-19, hepatitis A, hepatitis B, influenza, human papillomavirus and travel vaccines. Adverse events reported following both co-administration and MVA-BN vaccination alone were mild and short-lived, with very few participants seeking medical care.
The findings provide preliminary evidence supporting the safe co-administration of MVA-BN mpox vaccine with other adult vaccines and may help inform future immunisation policy and public health recommendations.
Access the study
